Cargando…
Lack of the effect of lobeglitazone, a peroxisome proliferator-activated receptor-γ agonist, on the pharmacokinetics and pharmacodynamics of warfarin
AIMS: Lobeglitazone has been developed for the treatment of type 2 diabetes mellitus. This study was conducted to evaluate potential drug–drug interactions between lobeglitazone and warfarin, an anticoagulant with a narrow therapeutic index. METHODS: In this open-label, three-treatment, crossover st...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4354432/ https://www.ncbi.nlm.nih.gov/pubmed/25767371 http://dx.doi.org/10.2147/DDDT.S76591 |
_version_ | 1782360763227176960 |
---|---|
author | Jung, Jin Ah Lee, Soo-Yun Kim, Tae-Eun Kim, Jung-Ryul Kim, Chin Huh, Wooseong Ko, Jae-Wook |
author_facet | Jung, Jin Ah Lee, Soo-Yun Kim, Tae-Eun Kim, Jung-Ryul Kim, Chin Huh, Wooseong Ko, Jae-Wook |
author_sort | Jung, Jin Ah |
collection | PubMed |
description | AIMS: Lobeglitazone has been developed for the treatment of type 2 diabetes mellitus. This study was conducted to evaluate potential drug–drug interactions between lobeglitazone and warfarin, an anticoagulant with a narrow therapeutic index. METHODS: In this open-label, three-treatment, crossover study, 24 healthy male subjects were administered lobeglitazone (0.5 mg) for 1–12 days with warfarin (25 mg) on day 5 in one period. After a washout interval, subjects were administered warfarin (25 mg) alone in the other period. Pharmacokinetics of R- and S-warfarin and lobeglitazone, as well as pharmacodynamics of warfarin, as measured by international normalized ratio (INR) and factor VII activity, were assessed. RESULTS: The geometric mean ratios (GMRs) and 90% confidence intervals (CIs) for area under the curve from time zero to the time of the last quantifiable concentration (AUC(last)) for warfarin + lobeglitazone: warfarin alone were 1.0076 (90% CI: 0.9771, 1.0391) for R-warfarin and 0.9880 (90% CI: 0.9537, 1.0235) for S-warfarin. The maximum observed plasma concentration (C(max)) values were 1.0167 (90% CI: 0.9507, 1.0872) for R-warfarin and 1.0028 (90% CI: 0.9518, 1.0992) for S-warfarin, both of which were contained in the interval 0.80–1.25. Lobeglitazone had no effect on the area under the effect–time curve from time 0 to 168 hours (AUEC) of INR and factor VII activity, as demonstrated by the GMRs of 1.0091 (90% CI: 0.9872, 1.0314) and 0.9355 (90% CI: 0.9028, 0.9695), respectively. In addition, the pharmacokinetics of lobeglitazone was also unaffected by warfarin. CONCLUSION: Concomitant administration of lobeglitazone and warfarin was well tolerated. Lobeglitazone had no meaningful effect on the pharmacokinetics or pharmacodynamics of warfarin. These findings indicate that lobeglitazone and warfarin can be coadministered without dosage adjustments for either drug. |
format | Online Article Text |
id | pubmed-4354432 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-43544322015-03-12 Lack of the effect of lobeglitazone, a peroxisome proliferator-activated receptor-γ agonist, on the pharmacokinetics and pharmacodynamics of warfarin Jung, Jin Ah Lee, Soo-Yun Kim, Tae-Eun Kim, Jung-Ryul Kim, Chin Huh, Wooseong Ko, Jae-Wook Drug Des Devel Ther Original Research AIMS: Lobeglitazone has been developed for the treatment of type 2 diabetes mellitus. This study was conducted to evaluate potential drug–drug interactions between lobeglitazone and warfarin, an anticoagulant with a narrow therapeutic index. METHODS: In this open-label, three-treatment, crossover study, 24 healthy male subjects were administered lobeglitazone (0.5 mg) for 1–12 days with warfarin (25 mg) on day 5 in one period. After a washout interval, subjects were administered warfarin (25 mg) alone in the other period. Pharmacokinetics of R- and S-warfarin and lobeglitazone, as well as pharmacodynamics of warfarin, as measured by international normalized ratio (INR) and factor VII activity, were assessed. RESULTS: The geometric mean ratios (GMRs) and 90% confidence intervals (CIs) for area under the curve from time zero to the time of the last quantifiable concentration (AUC(last)) for warfarin + lobeglitazone: warfarin alone were 1.0076 (90% CI: 0.9771, 1.0391) for R-warfarin and 0.9880 (90% CI: 0.9537, 1.0235) for S-warfarin. The maximum observed plasma concentration (C(max)) values were 1.0167 (90% CI: 0.9507, 1.0872) for R-warfarin and 1.0028 (90% CI: 0.9518, 1.0992) for S-warfarin, both of which were contained in the interval 0.80–1.25. Lobeglitazone had no effect on the area under the effect–time curve from time 0 to 168 hours (AUEC) of INR and factor VII activity, as demonstrated by the GMRs of 1.0091 (90% CI: 0.9872, 1.0314) and 0.9355 (90% CI: 0.9028, 0.9695), respectively. In addition, the pharmacokinetics of lobeglitazone was also unaffected by warfarin. CONCLUSION: Concomitant administration of lobeglitazone and warfarin was well tolerated. Lobeglitazone had no meaningful effect on the pharmacokinetics or pharmacodynamics of warfarin. These findings indicate that lobeglitazone and warfarin can be coadministered without dosage adjustments for either drug. Dove Medical Press 2015-03-02 /pmc/articles/PMC4354432/ /pubmed/25767371 http://dx.doi.org/10.2147/DDDT.S76591 Text en © 2015 Jung et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Jung, Jin Ah Lee, Soo-Yun Kim, Tae-Eun Kim, Jung-Ryul Kim, Chin Huh, Wooseong Ko, Jae-Wook Lack of the effect of lobeglitazone, a peroxisome proliferator-activated receptor-γ agonist, on the pharmacokinetics and pharmacodynamics of warfarin |
title | Lack of the effect of lobeglitazone, a peroxisome proliferator-activated receptor-γ agonist, on the pharmacokinetics and pharmacodynamics of warfarin |
title_full | Lack of the effect of lobeglitazone, a peroxisome proliferator-activated receptor-γ agonist, on the pharmacokinetics and pharmacodynamics of warfarin |
title_fullStr | Lack of the effect of lobeglitazone, a peroxisome proliferator-activated receptor-γ agonist, on the pharmacokinetics and pharmacodynamics of warfarin |
title_full_unstemmed | Lack of the effect of lobeglitazone, a peroxisome proliferator-activated receptor-γ agonist, on the pharmacokinetics and pharmacodynamics of warfarin |
title_short | Lack of the effect of lobeglitazone, a peroxisome proliferator-activated receptor-γ agonist, on the pharmacokinetics and pharmacodynamics of warfarin |
title_sort | lack of the effect of lobeglitazone, a peroxisome proliferator-activated receptor-γ agonist, on the pharmacokinetics and pharmacodynamics of warfarin |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4354432/ https://www.ncbi.nlm.nih.gov/pubmed/25767371 http://dx.doi.org/10.2147/DDDT.S76591 |
work_keys_str_mv | AT jungjinah lackoftheeffectoflobeglitazoneaperoxisomeproliferatoractivatedreceptorgagonistonthepharmacokineticsandpharmacodynamicsofwarfarin AT leesooyun lackoftheeffectoflobeglitazoneaperoxisomeproliferatoractivatedreceptorgagonistonthepharmacokineticsandpharmacodynamicsofwarfarin AT kimtaeeun lackoftheeffectoflobeglitazoneaperoxisomeproliferatoractivatedreceptorgagonistonthepharmacokineticsandpharmacodynamicsofwarfarin AT kimjungryul lackoftheeffectoflobeglitazoneaperoxisomeproliferatoractivatedreceptorgagonistonthepharmacokineticsandpharmacodynamicsofwarfarin AT kimchin lackoftheeffectoflobeglitazoneaperoxisomeproliferatoractivatedreceptorgagonistonthepharmacokineticsandpharmacodynamicsofwarfarin AT huhwooseong lackoftheeffectoflobeglitazoneaperoxisomeproliferatoractivatedreceptorgagonistonthepharmacokineticsandpharmacodynamicsofwarfarin AT kojaewook lackoftheeffectoflobeglitazoneaperoxisomeproliferatoractivatedreceptorgagonistonthepharmacokineticsandpharmacodynamicsofwarfarin |